OBJECTIVE: Thyroid-stimulating hormone (TSH) is a novel modulator of adipokine release from human and mouse adipocytes. The aim of our study was to identify the signal transduction pathways activated by TSH that stimulate interleukin (IL)-6 production. RESEARCH METHODS AND PROCEDURES: Mouse 3T3-L1 preadipocyte and differentiated adipocyte cell cultures were studied. The effect of 0 to 1 microM TSH on IL-6 protein release into the medium over 0 to 24 hours was assessed. TSH signaling pathways responsible for regulating IL-6 were studied through the use of 1 muM forskolin, 100 microM 8-pCPT-2'-O-Me-cAMP, 10 microM H89, 50 microM PD98059, and 2 mug/mL actinomycin D. RESULTS: TSH stimulated IL-6 release by 2.6-fold from 3T3-L1 adipocytes at concentrations as low as 0.01 microM but did not alter IL-6 production of corresponding preadipocytes. Forskolin (elevates intracellular cAMP) stimulated IL-6 release from 3T3-L1 adipocytes (n = 3, p < 0.005), and H89, an inhibitor of cAMP-dependent protein kinase A (PKA), reduced TSH-stimulated IL-6 release by 66% (n = 3, p < 0.01), indicating a requirement for cAMP-dependent PKA. Inhibition of the mitogen-activated protein kinase pathway with PD98059 did not affect TSH-stimulated IL-6 release. Activation of an alternate cAMP target, the exchange protein of cAMP, with 8-pCPT-2'-O-Me-cAMP, had no effect on IL-6 release. TSH raised the level of IL-6 mRNA, and blockade of transcription with actinomycin D abrogated IL-6 protein release by TSH (n = 3, p < 0.05). DISCUSSION: TSH stimulates IL-6 release from differentiated 3T3-L1 adipocytes, but not preadipocytes, by signaling through cAMP-PKA to activate IL-6 gene transcription.
OBJECTIVE: Thyroid-stimulating hormone (TSH) is a novel modulator of adipokine release from human and mouse adipocytes. The aim of our study was to identify the signal transduction pathways activated by TSH that stimulate interleukin (IL)-6 production. RESEARCH METHODS AND PROCEDURES: Mouse 3T3-L1 preadipocyte and differentiated adipocyte cell cultures were studied. The effect of 0 to 1 microM TSH on IL-6 protein release into the medium over 0 to 24 hours was assessed. TSH signaling pathways responsible for regulating IL-6 were studied through the use of 1 muM forskolin, 100 microM 8-pCPT-2'-O-Me-cAMP, 10 microM H89, 50 microM PD98059, and 2 mug/mL actinomycin D. RESULTS:TSH stimulated IL-6 release by 2.6-fold from 3T3-L1 adipocytes at concentrations as low as 0.01 microM but did not alter IL-6 production of corresponding preadipocytes. Forskolin (elevates intracellular cAMP) stimulated IL-6 release from 3T3-L1 adipocytes (n = 3, p < 0.005), and H89, an inhibitor of cAMP-dependent protein kinase A (PKA), reduced TSH-stimulated IL-6 release by 66% (n = 3, p < 0.01), indicating a requirement for cAMP-dependent PKA. Inhibition of the mitogen-activated protein kinase pathway with PD98059 did not affect TSH-stimulated IL-6 release. Activation of an alternate cAMP target, the exchange protein of cAMP, with 8-pCPT-2'-O-Me-cAMP, had no effect on IL-6 release. TSH raised the level of IL-6 mRNA, and blockade of transcription with actinomycin D abrogated IL-6 protein release by TSH (n = 3, p < 0.05). DISCUSSION: TSH stimulates IL-6 release from differentiated 3T3-L1 adipocytes, but not preadipocytes, by signaling through cAMP-PKA to activate IL-6 gene transcription.
Authors: A Tropeano; D Corica; S Curatola; A Li Pomi; C Casto; A Alibrandi; G Pepe; T Aversa; M Wasniewska Journal: J Endocrinol Invest Date: 2022-08-20 Impact factor: 5.467
Authors: Carmen L Soto-Rivera; Raina N Fichorova; Elizabeth N Allred; Linda J Van Marter; Bhavesh Shah; Camilia R Martin; Michael S D Agus; Alan Leviton Journal: Endocrine Date: 2014-07-06 Impact factor: 3.633